Table 5.
Expression levels of LINC00511, miR-185-3p, and miR-301a-3p in BC patient (n = 70) stratified group/subgroups.
| Characteristics | BC patients | LINC00511 | miR-185-3p | miR-301a-3p | ||
|---|---|---|---|---|---|---|
| n | % | Median (range) | Median (range) | Median (range) | ||
| Age (years) | ||||||
| ≤50 | 39 | 55.7 | 2.36 (0.01–21.48) | 0.48 (0.01–2.76) | 2.98 (0.14–20.4) | |
| >50 | 31 | 44.3 | 3.16 (0.65–21.78) | 0.62 (0.03–1.74) | 3.75 (0.46–20.6) | |
| p-value | NS | NS | NS | |||
| No. of offspring | ||||||
| ≤2 | 38 | 54.3 | 2.75 (0.65–20.11) | 0.4 (0.02–1.74) | 3.75 (0.14–20.4) | |
| >2 | 32 | 45.7 | 2.19 (0.01–21.78) | 0.63 (0.01–2.76) | 3.37 (0.14–20.6) | |
| p-value | NS | NS | NS | |||
| Non-Communicable Diseases | ||||||
| C.V.D | 32 | 45.7 | 2.18 (0.01–21.78) | 0.618 (0.0166–2.769) | 3.152 (0.444–20.62) | |
| D.M | 9 | 12.9 | 2.33 (1.559–11.26) | 0.303 (0.0718–1.74) | 3.361 (0.149–20.46) | |
| None | 29 | 41.4 | 2.69 (0.41–21.48) | 0.323 (0.0166–2.769) | 3.756 (0.149–20.48) | |
| p-value | NS | NS | NS | |||
| BC Family History | ||||||
| No | 54 | 77.1 | 2.31 (0.65–21.78) | 0.5682 (0.0166–2.769) | 3.338 (0.149–20.62) | |
| Yes | 16 | 22.9 | 4.17 (0.018–21.48) | 0.3009 (0.0166–2.769) | 5.434 (0.323–20.62) | |
| p-value | NS | NS | NS | |||
| Pt. Surgical History | ||||||
| No | 40 | 57.1 | 2.51 (0.018–21.78) | 0.5566 (0.0219–2.769) | 3.432 (0.149–20.62) | |
| Yes | 30 | 42.9 | 2.65 (0.41–21.48) | 0.5689 (0.0166–2.128) | 3.559 (0.323–19.69) | |
| p-value | NS | NS | NS | |||
| Hormonal Contraceptive intake | ||||||
| No | 53 | 75.7 | 2.59 (0.018–21.78) | 0.5701 (0.0349–2.769) | 4.225 (0.149–20.62) | |
| Yes | 17 | 24.3 | 2.33 (1.22–20.04) | 0.3207 (0.0166–1.197) | 1.027 (0.149–6.273) | |
| p-value | NS | NS | U=232; P= 0.0023* | |||
| TNM Stage | ||||||
| I-II (early stage) | 36 | 51.4 | 4.79 (0.73–21.78) | 0.474 (0.034–2.12) | 3.75 (0.154–20.62) | |
| III (late stage$) | 34 | 48.6 | 1.92 (0.018–17.16) | 0.576 (0.0166–2.76) | 3.15 (0.14–20.48) | |
| p-value | U = 313; p = 0.0003* | NS | NS | |||
| Tumor Size (cm) | ||||||
| ≤ 2 | 35 | 50 | 1.792 (0.018–12.73) | 0.747 (0.0166–2.76) | 1.39 (0.149–10.4) | |
| > 2 | 35 | 50 | 9.52 (0.41–21.78) | 0.251 (0.016–2.76) | 5.09 (0.46–20.62) | |
| p-value | U = 138; P< 0.0001* | U = 381; p = 0.0062* | U = 339; p = 0.0011* | |||
| Grade (Bloom–Richardson scale) | ||||||
| I/II | 55 | 78.6 | 2.29 (0.018–21.78) | 0.623 (0.02–2.76) | 3.75 (0.15–20.62) | |
| III/IV | 15 | 21.4 | 4.93 (1.97–17.16) | 0.188 (0.01–1.19) | 2.9 (0.149–20.48) | |
| p-value | U = 263; p = 0.031* | U = 222; p = 0.0056* | NS | |||
| LNM | ||||||
| No | 36 | 51.4 | 1.65 (0.417–11.26) | 0.727 (0.0166–2.76) | 3.33 (0.32–20.48) | |
| Yes | 34 | 48.6 | 10.41 (0.018–21.78) | 0.25 (0.0166–2.769) | 3.99 (0.14–20.62) | |
| p-value | U = 82; p < 0.0001* | U = 373; p = 0.0045* | NS | |||
| Histological BC type | ||||||
| IDC | 59 | 84.2 | 2.363 (0.018–21.78) | 0.57 (0.01–2.76) | 3.75 (0.14–20.62) | |
| Other types | 11 | 15.8 | 3.033 (1.23–20.04) | 0.32 (0.03–0.87) | 2.18 (0.32–20.11) | |
| p-value | NS | NS | NS | |||
| BC Molecular subtype | ||||||
| Luminal like | 51 | 72.8 | 3.03 (0.66–21.78) | 0.4828 (0.0166–2.128) | 3.361 (0.149–20.62) | |
| HER-2 overexpression | 16 | 22.8 | 1.59 (0.018–15.43) | 0.5761 (0.0166–2.769) | 6.023 (0.444–20.46) | |
| TNBC | 3 | 4.4 | 4.93 (1.65–17.16) | 0.6549 (0.054–0.9009) | 3.315 (0.641–20.48) | |
| p-value | H= 9.2; p = 0.0098* | NS | NS | |||
| ER status | ||||||
| Positive | 38 | 54.3 | 3.27 (0.66–21.48) | 0.47 (0.03–2.12) | 3.36 (0.14–10.4) | |
| Negative | 32 | 45.7 | 1.94 (0.018–21.78) | 0.57 (0.01–2.76) | 4.42 (0.32–20.62) | |
| p-value | U = 428; p = 0.0337* | NS | U = 423; p = 0.0417* | |||
| PR status | ||||||
| Positive | 50 | 71.4 | 3.02 (0.66–21.78) | 0.486 (0.016–2.12) | 3.39 (0.14–20.62) | |
| Negative | 20 | 28.6 | 1.63 (0.018–17.16) | 0.576 (0.01–2.76) | 4.76 (0.149–20.48) | |
| p-value | U = 317; p = 0.0039* | NS | NS | |||
| HER‐2/neu status | ||||||
| Positive | 23 | 32.9 | 2.01 (0.018–21.78) | 0.566 (0.016–2.12) | 3.36 (0.149–20.62) | |
| Negative | 47 | 67.1 | 2.69 (0.655–20.04) | 0.323 (0.0219–2.76) | 3.75 (0.323–20.62) | |
| p-value | NS | NS | NS | |||
| Ki-67 status | ||||||
| High | 10 | 14.2 | 2.865 (1.19–21.48) | 0.23 (0.04–1.08) | 2.98 (0.46–7.3) | |
| Low | 3 | 4.3 | 17.16 (1.65–20.04) | 0.65 (0.46–0.9) | 1.02 (0.64–3.31) | |
| N.A | 57 | 81.5 | – | – | – | |
| p-value | NS | NS | NS | |||
| CEA (ng/ml) | ||||||
| Cutoff ≤1.66 | 17 | 24.3 | 4.38 (0.41–21.78) | 0.30 (0.016–2.76) | 4.75 (0.14–20.62) | |
| Cutoff >1.66 | 53 | 75.7 | 2.36 (0.018–20.11) | 0.62 (0.03–0.9) | 3.31 (0.1–20.6) | |
| p-value | NS | NS | NS | |||
| CA15-3 (U/ml) | ||||||
| Cutoff ≤17.2 | 21 | 30 | 2.59 (1.47–16.87) | 0.57 (0.016–2.12) | 4.75 (0.32–20.62) | |
| Cutoff >17.2 | 49 | 70 | 2.42 (0.01–21.78) | 0.48 (0.01–2.71) | 3.43 (0.14–20.6) | |
| p-value | NS | NS | NS | |||
All data were expressed as median (range) and comparison was assessed using Mann–Whitney test (U) for comparison of two non-parametric groups and Kruskal–Wallis one-way ANOVA (H) for more than two non-parametric groups on GraphPad prism software. *Significant statistical difference less than 0.05, P statistical difference between BC subgroups, $late localized advanced stage [CVD, coronary vascular diseases; DM, diabetes mellitus; ER, estrogen receptor; HER-2, human epidermal growth factor receptor-2; IDC, invasive ductal carcinoma; LNM, lymph node metastasis; Ki-67, proliferative index; PR, progesterone receptor; TNBC; triple-negative breast cancer; TNM, tumor node metastasis; NS, Non Significant].